Project Grant F32AI195008
Award Date 10/11/26
Completion Date 8/31/29
Dollars Obligated $154K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University $909,998 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize antibody-mediated establishment of an SIV reservoir using an art-free approach. The project, designated R01AI198034, runs through January 31, 2031, with place of performance in Atlanta, Georgia. The research employs adeno-associated virus (AAV) vectors to deliver broadly neutralizing...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $149,190 on December 25, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel antiviral compounds targeting lenacapavir-resistant HIV. The research will characterize three novel capsid effectors designed to overcome resistance-associated mutations in HIV that render lenacapavir ineffective. The work comprises three aims: biochemical and biophysical assessment of each...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $430,375 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study HIV-1 fusion competence and the regulatory roles of spacer peptide 2 and matrix protein. The research combines quantitative investigation of how spacer peptide 2 (SP2) affects viral membrane properties and fusion to elucidate SP2's role in HIV-1 fusion competence. The study addresses findings that while...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $100,228 on February 18, 2027, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Assistance Type: Project Grant). The recipient will conduct structural and biochemical determination of the HIV-1 capsid nucleoporin 214 (NUP214) interaction. The work addresses the mechanism by which HIV-1 capsid cores traverse the nuclear pore complex to deliver viral genome and enable integration; it...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $909,998 on May 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a vaccination strategy against HIV using DNA-lipid nanoparticle technology. The research aims to induce strong and durable humoral and cellular immunity against HIV through DNA-LNP vaccination approaches that combine neutralizing antibody responses with CD8 T cell responses, including tissue-resident memory...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $234,750 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support molecular engineering research on immunoglobulin G3 (IgG3) therapeutic potential. The research addresses the underdevelopment of IgG3 as a clinical therapeutic agent despite its superior effector mechanism potency and flexible antigen-binding properties compared to other immunoglobulin subclasses. While...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $1,201,718 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and evaluate HIV vaccines using DNA and replicon RNA formulations combined with a lipid nanoparticle platform. The research compares two vaccine approaches—DNA/LION liposomes and replicon RNA/LION liposomes—both expressing membrane-bound stabilized HIV envelope trimers, alongside a GAG DNA/LION...
- <p>The National Institute of Allergy and Infectious Diseases awarded Emory University $234,750 on June 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Assistance Listing R21AI199526). The project focuses on tuberculosis proteomics research and runs through May 31, 2028, with place of performance in Atlanta, Georgia. Emory University's Office of Sponsored Programs Division serves as the recipient and will conduct the work.</p>
- The National Institute of Allergy and Infectious Diseases awarded Emory University $412,749 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into enhancers that facilitate genetic manipulation of specific B-cell subsets. The research identifies cis-regulatory elements (enhancers) that control cell-type and context-specific gene expression in memory B cells and antibody-secreting plasma cells, with the goal of developing precise genetic...
- Federal Grant Award Summary Emory University received a $160,546.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 3, 2025, through August 31, 2029. The project, titled "Towards Foundation Epidemic Models for Respiratory Infections: A Novel Spatiotemporal Machine Learning Framework," will be conducted at Emory's Atlanta, Georgia campus. This award...